ID   PTPRJ_HUMAN             Reviewed;        1337 AA.
AC   Q12913; Q15255; Q6P4H4; Q8NHM2; Q9UDA9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 3.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Receptor-type tyrosine-protein phosphatase eta;
DE            Short=Protein-tyrosine phosphatase eta;
DE            Short=R-PTP-eta;
DE            EC=3.1.3.48;
DE   AltName: Full=Density-enhanced phosphatase 1;
DE            Short=DEP-1;
DE   AltName: Full=HPTP eta;
DE   AltName: Full=Protein-tyrosine phosphatase receptor type J;
DE            Short=R-PTP-J;
DE   AltName: CD_antigen=CD148;
DE   Flags: Precursor;
GN   Name=PTPRJ; Synonyms=DEP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-872.
RX   PubMed=7937872; DOI=10.1073/pnas.91.21.9680;
RA   Oestman A., Yang Q., Tonks N.K.;
RT   "Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is
RT   enhanced with increasing cell density.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9680-9684(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ASP-872.
RX   PubMed=7994032;
RA   Honda H., Inazawa J., Nishida J., Yazaki Y., Hirai H.;
RT   "Molecular cloning, characterization, and chromosomal localization of
RT   a novel protein-tyrosine phosphatase, HPTP eta.";
RL   Blood 84:4186-4194(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-1337, AND VARIANTS CYS-214;
RP   PRO-276 AND ASP-872.
RC   TISSUE=Colon;
RX   PubMed=12089527; DOI=10.1038/ng903;
RA   Ruivenkamp C.A.L., van Wezel T., Zanon C., Stassen A.P.M., Vlcek C.,
RA   Csikos T., Klous A.M., Tripodis N., Perrakis A., Boerrigter L.,
RA   Groot P.C., Lindeman J., Mooi W.J., Meijjer G.A., Scholten G.,
RA   Dauwerse H., Paces V., van Zandwijk N., van Ommen G.J.B., Demant P.;
RT   "Ptprj is a candidate for the mouse colon-cancer susceptibility locus
RT   Scc1 and is frequently deleted in human cancers.";
RL   Nat. Genet. 31:295-300(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1124-1245 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Leukemia;
RX   PubMed=8483328;
RA   Honda H., Shibuya M., Chiba S., Yazaki Y., Hirai H.;
RT   "Identification of novel protein-tyrosine phosphatases in a human
RT   leukemia cell line, F-36P.";
RL   Leukemia 7:742-746(1993).
RN   [7]
RP   PROTEIN SEQUENCE OF 36-49; 485-502 AND 723-739, FUNCTION, TISSUE
RP   SPECIFICITY, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9531590;
RA   de la Fuente-Garcia M.A., Nicolas J.M., Freed J.H., Palou E.,
RA   Thomas A.P., Vilella R., Vives J., Gaya A.;
RT   "CD148 is a membrane protein tyrosine phosphatase present in all
RT   hematopoietic lineages and is involved in signal transduction on
RT   lymphocytes.";
RL   Blood 91:2800-2809(1998).
RN   [8]
RP   FUNCTION.
RX   PubMed=9780142;
RA   Tangye S.G., Wu J., Aversa G., de Vries J.E., Lanier L.L.,
RA   Phillips J.H.;
RT   "Negative regulation of human T cell activation by the receptor-type
RT   protein tyrosine phosphatase CD148.";
RL   J. Immunol. 161:3803-3807(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=10821867; DOI=10.1074/jbc.275.21.16219;
RA   Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E.,
RA   Vilella R., Bohmer F., Ostman A.;
RT   "Site-selective dephosphorylation of the platelet-derived growth
RT   factor beta-receptor by the receptor-like protein-tyrosine phosphatase
RT   DEP-1.";
RL   J. Biol. Chem. 275:16219-16226(2000).
RN   [10]
RP   FUNCTION.
RX   PubMed=11259588; DOI=10.1128/MCB.21.7.2393-2403.2001;
RA   Baker J.E., Majeti R., Tangye S.G., Weiss A.;
RT   "Protein tyrosine phosphatase CD148-mediated inhibition of T-cell
RT   receptor signal transduction is associated with reduced LAT and
RT   phospholipase Cgamma1 phosphorylation.";
RL   Mol. Cell. Biol. 21:2393-2403(2001).
RN   [11]
RP   FUNCTION.
RX   PubMed=12062403; DOI=10.1016/S0014-5793(02)02570-X;
RA   Persson C., Engstrom U., Mowbray S.L., Ostman A.;
RT   "Primary sequence determinants responsible for site-selective
RT   dephosphorylation of the PDGF beta-receptor by the receptor-like
RT   protein tyrosine phosphatase DEP-1.";
RL   FEBS Lett. 517:27-31(2002).
RN   [12]
RP   FUNCTION, INTERACTION WITH CTNNB1 AND JUP, MUTAGENESIS OF ASP-1205 AND
RP   CYS-1239, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=12370829; DOI=10.1038/sj.onc.1205858;
RA   Holsinger L.J., Ward K., Duffield B., Zachwieja J., Jallal B.;
RT   "The transmembrane receptor protein tyrosine phosphatase DEP1
RT   interacts with p120(ctn).";
RL   Oncogene 21:7067-7076(2002).
RN   [13]
RP   FUNCTION, INTERACTION WITH CTNNB1; GRB2; GAB1 AND JUP, AND MUTAGENESIS
RP   OF ASP-1205 AND CYS-1239.
RX   PubMed=12475979; DOI=10.1074/jbc.M210656200;
RA   Palka H.L., Park M., Tonks N.K.;
RT   "Hepatocyte growth factor receptor tyrosine kinase met is a substrate
RT   of the receptor protein-tyrosine phosphatase DEP-1.";
RL   J. Biol. Chem. 278:5728-5735(2003).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12913111; DOI=10.1083/jcb.200303040;
RA   Lin J., Weiss A.;
RT   "The tyrosine phosphatase CD148 is excluded from the immunologic
RT   synapse and down-regulates prolonged T cell signaling.";
RL   J. Cell Biol. 162:673-682(2003).
RN   [15]
RP   FUNCTION.
RX   PubMed=14709717; DOI=10.1242/jcs.00879;
RA   Kellie S., Craggs G., Bird I.N., Jones G.E.;
RT   "The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements,
RT   aberrant cell-substratum interactions and a reduction in cell
RT   proliferation.";
RL   J. Cell Sci. 117:609-618(2004).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-342; ASN-351; ASN-391 AND
RP   ASN-396.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [17]
RP   FUNCTION, AND MUTAGENESIS OF ASP-1205.
RX   PubMed=16778204; DOI=10.1158/0008-5472.CAN-06-0228;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RT   "The receptor-type protein tyrosine phosphatase J antagonizes the
RT   biochemical and biological effects of RET-derived oncoproteins.";
RL   Cancer Res. 66:6280-6287(2006).
RN   [18]
RP   FUNCTION.
RX   PubMed=16682945; DOI=10.1038/sj.onc.1209647;
RA   Balavenkatraman K.K., Jandt E., Friedrich K., Kautenburger T.,
RA   Pool-Zobel B.L., Ostman A., Bohmer F.D.;
RT   "DEP-1 protein tyrosine phosphatase inhibits proliferation and
RT   migration of colon carcinoma cells and is upregulated by protective
RT   nutrients.";
RL   Oncogene 25:6319-6324(2006).
RN   [19]
RP   FUNCTION, MUTAGENESIS OF ASP-1205, AND SUBCELLULAR LOCATION.
RX   PubMed=18348712; DOI=10.1042/BJ20071317;
RA   Tsuboi N., Utsunomiya T., Roberts R.L., Ito H., Takahashi K., Noda M.,
RA   Takahashi T.;
RT   "The tyrosine phosphatase CD148 interacts with the p85 regulatory
RT   subunit of phosphoinositide 3-kinase.";
RL   Biochem. J. 413:193-200(2008).
RN   [20]
RP   SUBUNIT.
RX   PubMed=19246339; DOI=10.1182/blood-2008-08-174318;
RA   Senis Y.A., Tomlinson M.G., Ellison S., Mazharian A., Lim J., Zhao Y.,
RA   Kornerup K.N., Auger J.M., Thomas S.G., Dhanjal T., Kalia N.,
RA   Zhu J.W., Weiss A., Watson S.P.;
RT   "The tyrosine phosphatase CD148 is an essential positive regulator of
RT   platelet activation and thrombosis.";
RL   Blood 113:4942-4954(2009).
RN   [21]
RP   FUNCTION IN EGFR REGULATION, MUTAGENESIS OF ASP-1205 AND CYS-1239, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19836242; DOI=10.1016/j.cub.2009.09.048;
RA   Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F.,
RA   Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.;
RT   "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase
RT   controlling EGFR endocytosis.";
RL   Curr. Biol. 19:1788-1798(2009).
RN   [22]
RP   FUNCTION, MUTAGENESIS OF ASP-1205 AND CYS-1239, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19332538; DOI=10.1074/jbc.M901901200;
RA   Sallee J.L., Burridge K.;
RT   "Density-enhanced phosphatase 1 regulates phosphorylation of tight
RT   junction proteins and enhances barrier function of epithelial cells.";
RL   J. Biol. Chem. 284:14997-15006(2009).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF LYS-1016 AND ASP-1205.
RX   PubMed=19494114; DOI=10.1074/jbc.M109.002758;
RA   Sacco F., Tinti M., Palma A., Ferrari E., Nardozza A.P.,
RA   Hooft van Huijsduijnen R., Takahashi T., Castagnoli L., Cesareni G.;
RT   "Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the
RT   RAS pathway by direct dephosphorylation of ERK1/2 kinases.";
RL   J. Biol. Chem. 284:22048-22058(2009).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-413 AND ASN-937.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [25]
RP   FUNCTION, AND MUTAGENESIS OF ASP-1205 AND CYS-1239.
RX   PubMed=18936167; DOI=10.1128/MCB.01374-08;
RA   Chabot C., Spring K., Gratton J.P., Elchebly M., Royal I.;
RT   "New role for the protein tyrosine phosphatase DEP-1 in Akt activation
RT   and endothelial cell survival.";
RL   Mol. Cell. Biol. 29:241-253(2009).
RN   [26]
RP   FUNCTION.
RX   PubMed=21091576; DOI=10.1111/j.1750-3639.2010.00464.x;
RA   Petermann A., Haase D., Wetzel A., Balavenkatraman K.K., Tenev T.,
RA   Guhrs K.H., Friedrich S., Nakamura M., Mawrin C., Bohmer F.D.;
RT   "Loss of the protein-tyrosine phosphatase DEP-1/PTPRJ drives
RT   meningioma cell motility.";
RL   Brain Pathol. 21:405-418(2011).
RN   [27]
RP   FUNCTION.
RX   PubMed=19922411; DOI=10.1042/BJ20091413;
RA   Omerovic J., Clague M.J., Prior I.A.;
RT   "Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent
RT   negative regulators of PKB/Akt activation in Ras-mutated cancer
RT   cells.";
RL   Biochem. J. 426:65-72(2010).
RN   [28]
RP   FUNCTION, INTERACTION WITH FLT3, AND MUTAGENESIS OF ASP-1205 AND
RP   CYS-1239.
RX   PubMed=21262971; DOI=10.1074/jbc.M110.205021;
RA   Arora D., Stopp S., Bohmer S.A., Schons J., Godfrey R., Masson K.,
RA   Razumovskaya E., Ronnstrand L., Tanzer S., Bauer R., Bohmer F.D.,
RA   Muller J.P.;
RT   "Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase
RT   FLT3 signaling.";
RL   J. Biol. Chem. 286:10918-10929(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1009, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   STRUCTURE BY NMR OF 366-456.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the fourth FN3 domain of human receptor-type
RT   tyrosine-protein phosphatase eta.";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [31]
RP   VARIANTS PRO-276; GLN-326 AND ASP-872.
RX   PubMed=15378013; DOI=10.1038/sj.onc.1207766;
RA   Iuliano R., Le Pera I., Cristofaro C., Baudi F., Arturi F.,
RA   Pallante P., Martelli M.L., Trapasso F., Chiariotti L., Fusco A.;
RT   "The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid
RT   carcinogenesis.";
RL   Oncogene 23:8432-8438(2004).
CC   -!- FUNCTION: Tyrosine phosphatase which dephosphorylates or
CC       contributes to the dephosphorylation of CTNND1, FLT3, PDGFRB, MET,
CC       RET (variant MEN2A), KDR, LYN, SRC, MAPK1, MAPK3, EGFR, TJP1,
CC       OCLN, PIK3R1 and PIK3R2. Plays a role in cell adhesion, migration,
CC       proliferation and differentiation. Involved in vascular
CC       development. Regulator of macrophage adhesion and spreading.
CC       Positively affects cell-matrix adhesion. Positive regulator of
CC       platelet activation and thrombosis. Negative regulator of cell
CC       proliferation. Negative regulator of PDGF-stimulated cell
CC       migration; through dephosphorylation of PDGFR. Positive regulator
CC       of endothelial cell survival, as well as of VEGF-induced SRC and
CC       AKT activation; through KDR dephosphorylation. Negative regulator
CC       of EGFR signaling pathway; through EGFR dephosphorylation.
CC       Enhances the barrier function of epithelial junctions during
CC       reassembly. Negatively regulates T-cell receptor (TCR) signaling.
CC       Upon T-cell TCR activation, it is up-regulated and excluded from
CC       the immunological synapses, while upon T-cell-antigen presenting
CC       cells (APC) disengagement, it is no longer excluded and can
CC       dephosphorylate PLCG1 and LAT to down-regulate prolongation of
CC       signaling. {ECO:0000269|PubMed:10821867,
CC       ECO:0000269|PubMed:11259588, ECO:0000269|PubMed:12062403,
CC       ECO:0000269|PubMed:12370829, ECO:0000269|PubMed:12475979,
CC       ECO:0000269|PubMed:12913111, ECO:0000269|PubMed:14709717,
CC       ECO:0000269|PubMed:16682945, ECO:0000269|PubMed:16778204,
CC       ECO:0000269|PubMed:18348712, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:19332538, ECO:0000269|PubMed:19494114,
CC       ECO:0000269|PubMed:19836242, ECO:0000269|PubMed:19922411,
CC       ECO:0000269|PubMed:21091576, ECO:0000269|PubMed:21262971,
CC       ECO:0000269|PubMed:9531590, ECO:0000269|PubMed:9780142}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- SUBUNIT: Monomer. Interacts with CTNNB1 (phosphorylated) and JUP
CC       (phosphorylated). Interacts with FLT3 (phosphorylated). Interacts
CC       with GAB1 and GRB2. {ECO:0000269|PubMed:12370829,
CC       ECO:0000269|PubMed:12475979, ECO:0000269|PubMed:19246339,
CC       ECO:0000269|PubMed:21262971}.
CC   -!- INTERACTION:
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-2264500, EBI-491549;
CC       O60716:CTNND1; NbExp=5; IntAct=EBI-2264500, EBI-701927;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-2264500, EBI-641062;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-2264500, EBI-1026718;
CC       P36888:FLT3; NbExp=3; IntAct=EBI-2264500, EBI-3946257;
CC       Q13480:GAB1; NbExp=2; IntAct=EBI-2264500, EBI-517684;
CC       P10912:GHR; NbExp=2; IntAct=EBI-2264500, EBI-286316;
CC       P35968:KDR; NbExp=4; IntAct=EBI-2264500, EBI-1005487;
CC       P28482:MAPK1; NbExp=7; IntAct=EBI-2264500, EBI-959949;
CC       P27361:MAPK3; NbExp=5; IntAct=EBI-2264500, EBI-73995;
CC       P08581:MET; NbExp=5; IntAct=EBI-2264500, EBI-1039152;
CC       P09619:PDGFRB; NbExp=4; IntAct=EBI-2264500, EBI-641237;
CC       Q02763:TEK; NbExp=2; IntAct=EBI-2264500, EBI-2257090;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Cell projection, ruffle membrane {ECO:0000250}. Cell
CC       junction. Note=After T-cell stimulation, it is temporarily
CC       excluded from immunological synapses.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q12913-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12913-2; Sequence=VSP_043652, VSP_043653;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in the promyelocytic cell line HL-
CC       60, the granulocyte-macrophage colony-stimulating factor-dependent
CC       leukemic cell line F-36P, and the IL3 and erythropoietin-dependent
CC       leukemic cell line F-36E. Expressed predominantly in epithelial
CC       cells and lymphocytes. Enhanced expression at high cell density.
CC       {ECO:0000269|PubMed:12370829, ECO:0000269|PubMed:8483328,
CC       ECO:0000269|PubMed:9531590}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:9531590}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Receptor class 3 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTPRJID41932ch11p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U10886; AAB36687.1; -; mRNA.
DR   EMBL; D37781; BAA07035.1; -; mRNA.
DR   EMBL; AC026975; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC103828; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC063417; AAH63417.1; -; mRNA.
DR   EMBL; AH011675; AAM69432.1; -; Genomic_DNA.
DR   CCDS; CCDS44596.1; -. [Q12913-2]
DR   CCDS; CCDS7945.1; -. [Q12913-1]
DR   PIR; I38670; I38670.
DR   RefSeq; NP_001091973.1; NM_001098503.1. [Q12913-2]
DR   RefSeq; NP_002834.3; NM_002843.3. [Q12913-1]
DR   UniGene; Hs.318547; -.
DR   PDB; 2CFV; X-ray; 2.50 A; A=1019-1311.
DR   PDB; 2DLE; NMR; -; A=366-456.
DR   PDB; 2NZ6; X-ray; 2.30 A; A=1019-1311.
DR   PDBsum; 2CFV; -.
DR   PDBsum; 2DLE; -.
DR   PDBsum; 2NZ6; -.
DR   ProteinModelPortal; Q12913; -.
DR   SMR; Q12913; -.
DR   BioGrid; 111759; 22.
DR   IntAct; Q12913; 65.
DR   MINT; MINT-1349281; -.
DR   STRING; 9606.ENSP00000400010; -.
DR   BindingDB; Q12913; -.
DR   ChEMBL; CHEMBL3692; -.
DR   DEPOD; Q12913; -.
DR   iPTMnet; Q12913; -.
DR   PhosphoSitePlus; Q12913; -.
DR   BioMuta; PTPRJ; -.
DR   DMDM; 166899088; -.
DR   EPD; Q12913; -.
DR   MaxQB; Q12913; -.
DR   PaxDb; Q12913; -.
DR   PeptideAtlas; Q12913; -.
DR   PRIDE; Q12913; -.
DR   DNASU; 5795; -.
DR   Ensembl; ENST00000418331; ENSP00000400010; ENSG00000149177. [Q12913-1]
DR   Ensembl; ENST00000440289; ENSP00000409733; ENSG00000149177. [Q12913-2]
DR   GeneID; 5795; -.
DR   KEGG; hsa:5795; -.
DR   UCSC; uc001ngo.5; human. [Q12913-1]
DR   CTD; 5795; -.
DR   DisGeNET; 5795; -.
DR   GeneCards; PTPRJ; -.
DR   H-InvDB; HIX0035923; -.
DR   HGNC; HGNC:9673; PTPRJ.
DR   HPA; HPA006026; -.
DR   MalaCards; PTPRJ; -.
DR   MIM; 600925; gene.
DR   neXtProt; NX_Q12913; -.
DR   OpenTargets; ENSG00000149177; -.
DR   PharmGKB; PA34018; -.
DR   eggNOG; KOG0791; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136384; -.
DR   HOGENOM; HOG000232054; -.
DR   HOVERGEN; HBG053761; -.
DR   InParanoid; Q12913; -.
DR   KO; K05698; -.
DR   PhylomeDB; Q12913; -.
DR   TreeFam; TF351926; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   SignaLink; Q12913; -.
DR   SIGNOR; Q12913; -.
DR   ChiTaRS; PTPRJ; human.
DR   EvolutionaryTrace; Q12913; -.
DR   GeneWiki; PTPRJ; -.
DR   GenomeRNAi; 5795; -.
DR   PRO; PR:Q12913; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000149177; -.
DR   CleanEx; HS_PTPRJ; -.
DR   ExpressionAtlas; Q12913; baseline and differential.
DR   Genevisible; Q12913; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0001772; C:immunological synapse; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0070097; F:delta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0045295; F:gamma-catenin binding; IPI:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0016791; F:phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0060242; P:contact inhibition; NAS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0010642; P:negative regulation of platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043116; P:negative regulation of vascular permeability; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00063; FN3; 5.
DR   Gene3D; 2.60.40.10; -; 8.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00060; FN3; 8.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS50853; FN3; 6.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; Complete proteome; Direct protein sequencing;
KW   Glycoprotein; Hydrolase; Membrane; Phosphoprotein; Polymorphism;
KW   Protein phosphatase; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL        1     35       {ECO:0000255}.
FT   CHAIN        36   1337       Receptor-type tyrosine-protein
FT                                phosphatase eta.
FT                                /FTId=PRO_0000025444.
FT   TOPO_DOM     36    975       Extracellular. {ECO:0000255}.
FT   TRANSMEM    976    996       Helical. {ECO:0000255}.
FT   TOPO_DOM    997   1337       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      121    209       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      207    291       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      271    364       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      368    456       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      457    541       Fibronectin type-III 5.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      542    623       Fibronectin type-III 6.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      625    720       Fibronectin type-III 7.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      721    817       Fibronectin type-III 8.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      816    902       Fibronectin type-III 9.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN     1041   1298       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION     1239   1245       Substrate binding. {ECO:0000250}.
FT   ACT_SITE   1239   1239       Phosphocysteine intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160,
FT                                ECO:0000255|PROSITE-ProRule:PRU10044}.
FT   BINDING    1205   1205       Substrate. {ECO:0000250}.
FT   BINDING    1283   1283       Substrate. {ECO:0000250}.
FT   MOD_RES    1009   1009       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     72     72       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     82     82       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     93     93       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    104    104       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    142    142       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    172    172       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    192    192       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    231    231       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    278    278       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    342    342       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    351    351       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    376    376       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    391    391       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    396    396       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    431    431       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    501    501       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    525    525       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    536    536       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    582    582       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    603    603       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    618    618       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    628    628       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    637    637       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    666    666       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    669    669       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    761    761       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    772    772       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    784    784       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    790    790       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    824    824       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    910    910       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    937    937       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   VAR_SEQ     539    539       V -> G (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043652.
FT   VAR_SEQ     540   1337       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043653.
FT   VARIANT     214    214       R -> C (in a colon cancer sample; somatic
FT                                mutation; dbSNP:rs121434507).
FT                                {ECO:0000269|PubMed:12089527}.
FT                                /FTId=VAR_015905.
FT   VARIANT     276    276       Q -> P (in a colon cancer sample; somatic
FT                                mutation; dbSNP:rs1566734).
FT                                {ECO:0000269|PubMed:12089527,
FT                                ECO:0000269|PubMed:15378013}.
FT                                /FTId=VAR_015906.
FT   VARIANT     293    293       A -> T (in dbSNP:rs2229701).
FT                                /FTId=VAR_038414.
FT   VARIANT     326    326       R -> Q (in dbSNP:rs1503185).
FT                                {ECO:0000269|PubMed:15378013}.
FT                                /FTId=VAR_024582.
FT   VARIANT     372    372       V -> I (in dbSNP:rs2229703).
FT                                /FTId=VAR_038415.
FT   VARIANT     872    872       E -> D (in dbSNP:rs4752904).
FT                                {ECO:0000269|PubMed:12089527,
FT                                ECO:0000269|PubMed:15378013,
FT                                ECO:0000269|PubMed:7937872,
FT                                ECO:0000269|PubMed:7994032}.
FT                                /FTId=VAR_038416.
FT   VARIANT    1235   1235       I -> T (in dbSNP:rs11039554).
FT                                /FTId=VAR_038417.
FT   MUTAGEN    1016   1016       K->A: 80% decrease in interaction with
FT                                MAPK1 and MAPK3.
FT                                {ECO:0000269|PubMed:19494114}.
FT   MUTAGEN    1205   1205       D->A: Substrate trapping with much higher
FT                                affinity for substrate.
FT                                {ECO:0000269|PubMed:12370829,
FT                                ECO:0000269|PubMed:12475979,
FT                                ECO:0000269|PubMed:16778204,
FT                                ECO:0000269|PubMed:18348712,
FT                                ECO:0000269|PubMed:18936167,
FT                                ECO:0000269|PubMed:19332538,
FT                                ECO:0000269|PubMed:19494114,
FT                                ECO:0000269|PubMed:19836242,
FT                                ECO:0000269|PubMed:21262971}.
FT   MUTAGEN    1239   1239       C->S: Catalytically inactive and
FT                                substrate trapping with higher affinity
FT                                for substrate.
FT                                {ECO:0000269|PubMed:12370829,
FT                                ECO:0000269|PubMed:12475979,
FT                                ECO:0000269|PubMed:18936167,
FT                                ECO:0000269|PubMed:19332538,
FT                                ECO:0000269|PubMed:19836242,
FT                                ECO:0000269|PubMed:21262971}.
FT   CONFLICT    261    261       G -> D (in Ref. 1; AAB36687).
FT                                {ECO:0000305}.
FT   CONFLICT    918    929       YNGKLEPLGSYR -> LQWEAGTSGLLP (in Ref. 2;
FT                                BAA07035). {ECO:0000305}.
FT   CONFLICT   1130   1130       K -> Q (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT   1234   1234       P -> E (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT   1243   1243       V -> I (in Ref. 6; no nucleotide entry).
FT                                {ECO:0000305}.
FT   STRAND      368    377       {ECO:0000244|PDB:2DLE}.
FT   STRAND      382    389       {ECO:0000244|PDB:2DLE}.
FT   STRAND      398    404       {ECO:0000244|PDB:2DLE}.
FT   STRAND      409    420       {ECO:0000244|PDB:2DLE}.
FT   STRAND      429    440       {ECO:0000244|PDB:2DLE}.
FT   STRAND      446    451       {ECO:0000244|PDB:2DLE}.
FT   HELIX      1023   1047       {ECO:0000244|PDB:2NZ6}.
FT   TURN       1048   1054       {ECO:0000244|PDB:2NZ6}.
FT   TURN       1058   1061       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1063   1068       {ECO:0000244|PDB:2NZ6}.
FT   TURN       1078   1080       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1087   1089       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1090   1093       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1096   1100       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1108   1113       {ECO:0000244|PDB:2NZ6}.
FT   TURN       1117   1119       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1120   1129       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1134   1138       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1155   1157       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1159   1161       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1164   1173       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1175   1186       {ECO:0000244|PDB:2NZ6}.
FT   TURN       1187   1189       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1192   1200       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1212   1225       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1235   1243       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1244   1261       {ECO:0000244|PDB:2NZ6}.
FT   STRAND     1262   1265       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1267   1275       {ECO:0000244|PDB:2NZ6}.
FT   HELIX      1285   1302       {ECO:0000244|PDB:2NZ6}.
SQ   SEQUENCE   1337 AA;  145941 MW;  B44F4343FC8FD1B4 CRC64;
     MKPAAREARL PPRSPGLRWA LPLLLLLLRL GQILCAGGTP SPIPDPSVAT VATGENGITQ
     ISSTAESFHK QNGTGTPQVE TNTSEDGESS GANDSLRTPE QGSNGTDGAS QKTPSSTGPS
     PVFDIKAVSI SPTNVILTWK SNDTAASEYK YVVKHKMENE KTITVVHQPW CNITGLRPAT
     SYVFSITPGI GNETWGDPRV IKVITEPIPV SDLRVALTGV RKAALSWSNG NGTASCRVLL
     ESIGSHEELT QDSRLQVNIS GLKPGVQYNI NPYLLQSNKT KGDPLGTEGG LDASNTERSR
     AGSPTAPVHD ESLVGPVDPS SGQQSRDTEV LLVGLEPGTR YNATVYSQAA NGTEGQPQAI
     EFRTNAIQVF DVTAVNISAT SLTLIWKVSD NESSSNYTYK IHVAGETDSS NLNVSEPRAV
     IPGLRSSTFY NITVCPVLGD IEGTPGFLQV HTPPVPVSDF RVTVVSTTEI GLAWSSHDAE
     SFQMHITQEG AGNSRVEITT NQSIIIGGLF PGTKYCFEIV PKGPNGTEGA SRTVCNRTVP
     SAVFDIHVVY VTTTEMWLDW KSPDGASEYV YHLVIESKHG SNHTSTYDKA ITLQGLIPGT
     LYNITISPEV DHVWGDPNST AQYTRPSNVS NIDVSTNTTA ATLSWQNFDD ASPTYSYCLL
     IEKAGNSSNA TQVVTDIGIT DATVTELIPG SSYTVEIFAQ VGDGIKSLEP GRKSFCTDPA
     SMASFDCEVV PKEPALVLKW TCPPGANAGF ELEVSSGAWN NATHLESCSS ENGTEYRTEV
     TYLNFSTSYN ISITTVSCGK MAAPTRNTCT TGITDPPPPD GSPNITSVSH NSVKVKFSGF
     EASHGPIKAY AVILTTGEAG HPSADVLKYT YEDFKKGASD TYVTYLIRTE EKGRSQSLSE
     VLKYEIDVGN ESTTLGYYNG KLEPLGSYRA CVAGFTNITF HPQNKGLIDG AESYVSFSRY
     SDAVSLPQDP GVICGAVFGC IFGALVIVTV GGFIFWRKKR KDAKNNEVSF SQIKPKKSKL
     IRVENFEAYF KKQQADSNCG FAEEYEDLKL VGISQPKYAA ELAENRGKNR YNNVLPYDIS
     RVKLSVQTHS TDDYINANYM PGYHSKKDFI ATQGPLPNTL KDFWRMVWEK NVYAIIMLTK
     CVEQGRTKCE EYWPSKQAQD YGDITVAMTS EIVLPEWTIR DFTVKNIQTS ESHPLRQFHF
     TSWPDHGVPD TTDLLINFRY LVRDYMKQSP PESPILVHCS AGVGRTGTFI AIDRLIYQIE
     NENTVDVYGI VYDLRMHRPL MVQTEDQYVF LNQCVLDIVR SQKDSKVDLI YQNTTAMTIY
     ENLAPVTTFG KTNGYIA
//
